Abstract: The present invention relates to a touch display device, a drive control circuit for the touch display device, and a method for operating the touch display device. The touch display device includes a drive control circuit, the drive control circuit is configured to: in a display phase, provide a common voltage signal to a common electrode in a pixel circuit of the touch display device; in a touch phase, provide a touch drive signal to the common electrode, wherein a ratio of an average value of a high level and a low level of the touch drive signal to a value of the common voltage signal ranges from 0.8 to 1.2.

Abstract: Provided herein are methods of treating prostate cancer having at least one pathogenic AR mutation using 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3- yl)methyl)benzo[d][1,3]dioxole-5-carboxamide, or a pharmaceutically acceptable salt thereof, alone or in combination with a therapeutically effective amount of an androgen receptor signaling inhibitor (ARSI) such as enzalutamide.

Abstract: A light-emitting substrate, a display panel, a backlight module, a display device and a driving method. The light-emitting substrate has a light-emitting region and includes a plurality of light-emitting elements located in the light-emitting region and configured to emit light of different colors. The plurality of light-emitting elements includes an edge light-emitting element adjacent to an edge of the light-emitting region, and a first light-emitting element adjacent to the edge light-emitting element, and the edge light-emitting element is configured to emit light of a first color, and the first light-emitting element is configured to emit light of a second color different from the first color.

Abstract: The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly[ADP-ribose] polymerase (PARP) signaling.

Abstract: The present invention provides methods of treatment for cancer(s) through combination therapy with an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling and an agent that regulates activity within the tumor microenvironment.

Abstract: The present invention provides methods of treatment for cancer(s) through combination therapy with an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling and an agent that regulates activity within the tumor microenvironment.

Abstract: The present invention provides methods of treatment for cancer through combination therapy with an agent that inhibits programmed death-1 protein (PD-1) signaling and an agent that inhibits poly [ADP-ribose] polymerase (PARP) signaling.

Abstract: An assembly includes a base. The assembly includes a plate pivotally supported by the base. The assembly includes a seatbelt retractor supported by the plate. The assembly includes a webbing payable from the seatbelt retractor.

Abstract: An assembly includes a base. The assembly includes a plate pivotally supported by the base. The assembly includes a seatbelt retractor supported by the plate. The assembly includes a webbing payable from the seatbelt retractor.